US researchers have started a clinical trial to test what happens when adults who have been fully vaccinated with one type of Covid-19 vaccine receive booster doses of a different Covid-19 vaccine.
The trial aims to determine the safety and immunogenicity of mixed boosted regimens, according to the US National Institutes of Health (NIH), Xinhua reported.
The trial will include about 150 adults who have been fully vaccinated with one of the three approved Covid-19 vaccines in the United States, the Johnson & Johnson, Moderna or Pfizer vaccines.
Each vaccine group will enroll about 25 people aged 18 to 55 years, and about 25 people aged 56 years and older. Twelve to 20 weeks following their initial vaccination regimen, participants will receive a single booster dose of the Moderna Covid-19 vaccine as part of the trial.
People who have not received Covid-19 vaccine are also eligible to enroll in the trial in a separate cohort. These volunteers will initially receive the two-dose Moderna Covid-19 vaccine regimen, and will be assigned to receive a booster dose of a vaccine about 12 to 20 weeks later, according to the NIH.
Trial investigators will evaluate participants for safety and any side effects after vaccination. Participants also will be asked to provide blood samples periodically so that trial investigators can evaluate immune responses against current circulating strains of SARS-CoV-2, as well as emerging variants, according to the NIH.
Initial trial results are expected in late summer this year.
--IANS
int/pgh
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU